within Pharmacolibrary.Drugs.ATC.A;

model A10BB06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 0.025,
    adminDuration  = 600,
    adminMass      = 0.5,
    adminCount     = 1,
    Vd             = 0.016,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Carbutamide is a first-generation sulfonylurea oral hypoglycemic drug historically used to treat type 2 diabetes mellitus. It acts by stimulating insulin secretion from pancreatic beta-cells. Carbutamide is largely obsolete and is not commonly used in clinical practice today due to safer alternatives with better efficacy and lower risk of adverse effects.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for a typical adult (based on pharmacological class analogs and limited historical data). No recent or direct human PK studies with full parameterization are available for carbutamide.</p><h4>References</h4><ol><li><p>Berger, W, &amp; Spring, P (1970). [Changes of pharmacokinetics of oral antidiabetics from drug interference and renal insufficiency]. <i>Deutsche medizinische Wochenschrift (1946)</i> 95(50) 2525â€“2527. DOI:<a href=&quot;https://doi.org/10.1055/s-0028-1108869&quot;>10.1055/s-0028-1108869</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/5488752/&quot;>https://pubmed.ncbi.nlm.nih.gov/5488752</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10BB06;
